Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapyEmanuele Zucca, Eva Kimby, Andrés J.M. Ferreri et al.|Blood|2019Cited by 61
Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10Eva Kimby, Emanuele Zucca, Giovanni Martinelli et al.|Blood|2014Cited by 18
Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10Eva Kimby, Emanuele Zucca, Stéphanie Rondeau et al.|Blood|2016Cited by 9
Incidence of hypocalcemia in a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w): SAKK 96/12 (REDUSE)Roger von Moos, Arnoud J. Templeton, Hanne Hawle et al.|Annals of Oncology|2018Cited by 4
Abstract P1-18-01: Incidence of hypocalcemia in patients with metastatic breast cancer under treatment with denosumab: A non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab administered every 4 weeks versus every 12 weeks: SAKK 96/12 (REDUSE)AMANDA OLGA MÜLLER, Roger von Moos, AJ Templeton et al.|Cancer Research|2019Cited by 2